SlideShare a Scribd company logo
Presented by: Arjan Aryal
5th PharmD
Patients with ESRD or who have been
intoxicated due to overdose of a drug may require
supported treatment to remove accumulated
drugs.
 Methods:
Dialysis
Hemofiltration
Hemoperfusion.
 Objective:
Rapidly remove undesirable drugs and
metabolites without disturbing the fluid and electrolyte
balance in the patient.
 Artificial Process, acculmulation of drug
removed by diffusion into dialysis fluid.
 Two Methods:
 Peritoneal Dialysis.
 Hemodialysis.
 Helps to clean the blood and remove
excess of water in the body – peritoneal
Membrane in the abdomen.
 A catheter inserted in peritoneal cavity,
dialysis fluid enters into the peritoneal
cavity via tube -> filters blood and
remove waste products from the body.
 Two Types
 CAPD(Continous Ambulatory Peritoneal Dialysis)))
 APD (Automated Peritoneal Dialysis)
 Fluid flows in and out of the body using
gravity.
 Over time, waste and fluid build up in the
blood which slowly float across into
peritoneal membrane by diffusion and
exchange remove dialysis fluid from the
peritoneal cavity and replaces with new fluid.
 To be done everyday
 1 Exchange takes 30 mins.
 Solution is clear.
 Check the solution type and % is correct.
 Expiration date has not passed.
 Volume is correct.
 No leaks after gentle squeezing.
 Machine does the exchange
 Done by Dialysis team or taught to use .
FLUID AND DIALYSIS SOLUTION
 Important to achieve right balance of water in body.
 Determined in 3 ways.
 Weight
 BP
 Swelling
 Dialysis Solution
 Dianeal (1.5%, 2.5%, 4.25%)
 Neutroneal (1.1 %)
 Extraneal (7.5%)
PRECAUTION
Infection
 Process that uses artificial kidney to remove waste products
through the process called diffusion.
 Artificial kidney contains a number of tubes with a semi
permeable lining, suspended in a tank filled with dialysing
fluid.
1.
•One line connected to artery which is connected to one end of dialysis where
blood is collected from patient for filtration.
2.
•Waste Product from the blood passes into dialysing fluid by diffusion.
3.
•Purified Blood is pumped back into the vein which is connected to other end
of dialysis device.
 Heparin is used to prevent blood clotting during dialysis.
 It is much more effective method for rapid removal of drug (
overdose , poisoning) and preferred method in ESRD.
 Dialysis may be required from every 2 days to 3 times a week,
one dialysis period is of 2-4 hrs depending on patient’s size,
weight and renal function.
CHARACTERISTICS OF DIALYSING MACHINE
 Higher Blood flow rate.
 Permeable dialysis membrane.
 High Transmembrane pressure.
Important notes.
•Insoluble or fat soluble drugs are not solubilized.( eg
glutethimide – a water insoluble drug.)
Water Solubility
•Tightly bound protein are not dialysed. (eg
propranolol)
Protein Binding
•Mol Wt less than 500 are dialysed. ( eg Vancomycin is
poorly dialysed )
Molecular Weight
Drugs with large
volume of distribution
•Widely distributed drugs are dialysed slowly, drug
concentrated in tissues are difficult to remove by
dialysis.
 In dialysis involving uremic patient receiving drug for therapy,
drug is removed depending on the flow rate of the blood to
the dialysis machine which is described by the term
Dialysance.
 Defined by the equation :
ClD = Q(Ca –CV)
Ca
where, Ca = Drug Concentration in arterial blood.
CV =Drug Concentration in Venous blood.
Q= Rate of Blood flow to kidney.
ClD = Dialysance.
 Removing the drugs by passing the blood
from the patient through an adsorbent
material and back to the patient.
 Molecules which have greater affinity for the
materials will be removed.
 Useful in accidental poisoning and drug
overdose.
 Materials use:
◦ Activated Charcoal (both polar and non polar drugs)
◦ Amberlite resins (non polar organic molecules).
 Affinity of the drug for the absorbent.
 Surface area of the absorbent.
 Absorptive capacity of the absorbent.
 Rate of blood flow through the absorbent.
 Equilibrium rate of the drug from the
peripheral tissue into the blood.
 An alternative to hemodialysis and
hemoperfusion.
 A process by which fluid, electrolytes, small
molecular weight substances are removed
from the blood using hollow artificial fibre.
 Loss of water and electrolytes takes place,
that leads to production of ultrafiltrate. As a
result equal volume of fluid is replaced.
 Synthetic, high flux(permeability), hollow fibre membrane.
 Pore size 50000 da
 High Surface Area ( 0.6-1.2 m2).
Notes
• Flow rate of 20-35 ml/kg/hr is usually required.
• No benefit shown with higher flow rate, more expensive.
• Although higher flow rate may be used if rapid solute
clearance is necessary.
Hemodialysis involves diffusion across a semipermeable membrane
Where as Hemofiltration is a convection process with loss of water
Due to ultrafiltration accompanied by convicted loss of salts.
 The clearance of the drug depends on sieving coefficient and
ultrafiltration rate.
 The sieving coefficient reflects the solute removal ability
during hemofiltration.
 When S=1 solute passes freely through the membrane
whereas is S=0 solute is retained in plasma.
 S is constant and independent of blood flow , so
Cl=S * Ultrafiltration rate
 The Concentration of the drug in the ultrafiltrate is also equal
to the unbound drug concentration in the plasma , so,
amount of drug removed is given as :
Amount removed = CP + ∞ * rate of ultrafiltration
Extracorporeal tech

More Related Content

What's hot

Dose adjustment in Renal failure
Dose adjustment in Renal failure Dose adjustment in Renal failure
Dose adjustment in Renal failure
Mallinath Paramgond
 
Extracorporeal removal of drugs
Extracorporeal removal of drugsExtracorporeal removal of drugs
Extracorporeal removal of drugs
Dr. Ramesh Bhandari
 
Dosing in elderly
Dosing in elderly Dosing in elderly
Dosing in elderly
Dr. Ramesh Bhandari
 
Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.
pavithra vinayak
 
Gastrointestinal absorption of drugs
Gastrointestinal absorption of drugsGastrointestinal absorption of drugs
Gastrointestinal absorption of drugs
Siddu K M
 
Drug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide shareDrug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide share
javvadhasan
 
Renal impariment
Renal imparimentRenal impariment
Renal impariment
Bahubali Patil
 
Population pharamacokinetics
Population pharamacokineticsPopulation pharamacokinetics
Population pharamacokinetics
Dr. Ramesh Bhandari
 
Pharmacological Approach to Drug Discovery
Pharmacological Approach to Drug DiscoveryPharmacological Approach to Drug Discovery
Pharmacological Approach to Drug Discovery
Suhas Reddy C
 
Genetic polymorphism of drug targets
Genetic polymorphism of drug targetsGenetic polymorphism of drug targets
Genetic polymorphism of drug targets
Dr. Ankit Gaur
 
Drug dose adjustment for liver diseases
Drug dose adjustment  for liver diseasesDrug dose adjustment  for liver diseases
Drug dose adjustment for liver diseases
Neha Suresh
 
dosage adjustment in renal and hepatic failure for medical student
dosage adjustment in renal and hepatic failure for medical studentdosage adjustment in renal and hepatic failure for medical student
dosage adjustment in renal and hepatic failure for medical student
DeepaJoshi41
 
Introduction to clinical pharmacokinetics
Introduction to clinical pharmacokineticsIntroduction to clinical pharmacokinetics
Introduction to clinical pharmacokinetics
Dr. Ramesh Bhandari
 
Dosing in childrens
Dosing in childrensDosing in childrens
Dosing in childrens
Dr. Ramesh Bhandari
 
Individualization of dosage regimen
Individualization of dosage regimenIndividualization of dosage regimen
Individualization of dosage regimen
PARUL UNIVERSITY
 
Drug induced birth defect
Drug induced birth defectDrug induced birth defect
Drug induced birth defect
Dr. Ashish singh parihar
 
DRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATIONDRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATION
aishuanju
 
Individualization of drug
Individualization of drugIndividualization of drug
Individualization of drug
Dr. Ramesh Bhandari
 
Effects of Liver disease on Pharmacokinetics
Effects of Liver disease on Pharmacokinetics Effects of Liver disease on Pharmacokinetics
Effects of Liver disease on Pharmacokinetics
Areej Abu Hanieh
 
Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology
ABUBAKRANSARI2
 

What's hot (20)

Dose adjustment in Renal failure
Dose adjustment in Renal failure Dose adjustment in Renal failure
Dose adjustment in Renal failure
 
Extracorporeal removal of drugs
Extracorporeal removal of drugsExtracorporeal removal of drugs
Extracorporeal removal of drugs
 
Dosing in elderly
Dosing in elderly Dosing in elderly
Dosing in elderly
 
Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.
 
Gastrointestinal absorption of drugs
Gastrointestinal absorption of drugsGastrointestinal absorption of drugs
Gastrointestinal absorption of drugs
 
Drug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide shareDrug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide share
 
Renal impariment
Renal imparimentRenal impariment
Renal impariment
 
Population pharamacokinetics
Population pharamacokineticsPopulation pharamacokinetics
Population pharamacokinetics
 
Pharmacological Approach to Drug Discovery
Pharmacological Approach to Drug DiscoveryPharmacological Approach to Drug Discovery
Pharmacological Approach to Drug Discovery
 
Genetic polymorphism of drug targets
Genetic polymorphism of drug targetsGenetic polymorphism of drug targets
Genetic polymorphism of drug targets
 
Drug dose adjustment for liver diseases
Drug dose adjustment  for liver diseasesDrug dose adjustment  for liver diseases
Drug dose adjustment for liver diseases
 
dosage adjustment in renal and hepatic failure for medical student
dosage adjustment in renal and hepatic failure for medical studentdosage adjustment in renal and hepatic failure for medical student
dosage adjustment in renal and hepatic failure for medical student
 
Introduction to clinical pharmacokinetics
Introduction to clinical pharmacokineticsIntroduction to clinical pharmacokinetics
Introduction to clinical pharmacokinetics
 
Dosing in childrens
Dosing in childrensDosing in childrens
Dosing in childrens
 
Individualization of dosage regimen
Individualization of dosage regimenIndividualization of dosage regimen
Individualization of dosage regimen
 
Drug induced birth defect
Drug induced birth defectDrug induced birth defect
Drug induced birth defect
 
DRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATIONDRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATION
 
Individualization of drug
Individualization of drugIndividualization of drug
Individualization of drug
 
Effects of Liver disease on Pharmacokinetics
Effects of Liver disease on Pharmacokinetics Effects of Liver disease on Pharmacokinetics
Effects of Liver disease on Pharmacokinetics
 
Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology
 

Viewers also liked

Ho Kok Yuen - Pump Delivery for Pain Management
Ho Kok Yuen - Pump Delivery for Pain ManagementHo Kok Yuen - Pump Delivery for Pain Management
Ho Kok Yuen - Pump Delivery for Pain Management
Department of Anesthesiology, Faculty of Medicine Hasanuddin University
 
Patient Controlled Analgesia: Return to Nursing Program
Patient Controlled Analgesia: Return to Nursing ProgramPatient Controlled Analgesia: Return to Nursing Program
Patient Controlled Analgesia: Return to Nursing Program
IHNA Australia
 
dr. Muh. Takdir - Patient Controlled Analgesia
dr. Muh. Takdir - Patient Controlled Analgesiadr. Muh. Takdir - Patient Controlled Analgesia
dr. Muh. Takdir - Patient Controlled Analgesia
Department of Anesthesiology, Faculty of Medicine Hasanuddin University
 
Dialysis various modalities and indices used
Dialysis various modalities and indices usedDialysis various modalities and indices used
Dialysis various modalities and indices usedAbhay Mange
 
Local Anaesthetics
Local AnaestheticsLocal Anaesthetics
Local Anaesthetics
http://neigrihms.gov.in/
 
Dialysis
DialysisDialysis
Dialysis
Roanna Martin
 
Dialysis basics
Dialysis basicsDialysis basics
Dialysis basics
Dr Ashutosh Ojha
 

Viewers also liked (8)

11 Peritoneal Dialysis
11 Peritoneal Dialysis11 Peritoneal Dialysis
11 Peritoneal Dialysis
 
Ho Kok Yuen - Pump Delivery for Pain Management
Ho Kok Yuen - Pump Delivery for Pain ManagementHo Kok Yuen - Pump Delivery for Pain Management
Ho Kok Yuen - Pump Delivery for Pain Management
 
Patient Controlled Analgesia: Return to Nursing Program
Patient Controlled Analgesia: Return to Nursing ProgramPatient Controlled Analgesia: Return to Nursing Program
Patient Controlled Analgesia: Return to Nursing Program
 
dr. Muh. Takdir - Patient Controlled Analgesia
dr. Muh. Takdir - Patient Controlled Analgesiadr. Muh. Takdir - Patient Controlled Analgesia
dr. Muh. Takdir - Patient Controlled Analgesia
 
Dialysis various modalities and indices used
Dialysis various modalities and indices usedDialysis various modalities and indices used
Dialysis various modalities and indices used
 
Local Anaesthetics
Local AnaestheticsLocal Anaesthetics
Local Anaesthetics
 
Dialysis
DialysisDialysis
Dialysis
 
Dialysis basics
Dialysis basicsDialysis basics
Dialysis basics
 

Similar to Extracorporeal tech

Continuous Renal Replacement Therapy
Continuous Renal Replacement TherapyContinuous Renal Replacement Therapy
Continuous Renal Replacement Therapy
Dhanya Raghu
 
renal replacement therapies
renal replacement therapiesrenal replacement therapies
renal replacement therapiesRia Saira
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
aratimohan
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
Dr Amrit Parihar
 
contious Renal replacement therapy
contious Renal replacement therapycontious Renal replacement therapy
contious Renal replacement therapy
Dr. Mohamed Maged Kharabish
 
Continuous renal replacement therapy in icu Crrt 2
 Continuous renal replacement therapy in icu Crrt  2 Continuous renal replacement therapy in icu Crrt  2
Continuous renal replacement therapy in icu Crrt 2
samirelansary
 
Hemodialysis: management of chronic kidney disease
Hemodialysis: management of chronic kidney diseaseHemodialysis: management of chronic kidney disease
Hemodialysis: management of chronic kidney disease
Sapana Shrestha
 
Continuous renal replacement therapy
Continuous renal replacement therapyContinuous renal replacement therapy
Continuous renal replacement therapy
saheli chakraborty
 
Crrt 2
Crrt  2Crrt  2
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt 2
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt  2CONTINUOUS RENAL REPLACEMENT THERAPY Crrt  2
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt 2
samirelansary
 
Hemodialysis
Hemodialysis Hemodialysis
Hemodialysis
Mohammad saleh Moallem
 
Renal dialysis
Renal dialysisRenal dialysis
Renal dialysis
ZeelNaik2
 
Hemodialysis
HemodialysisHemodialysis
Hemodialysis
DharmikMendapara
 
Basic principles of haemodialysis
Basic principles of haemodialysisBasic principles of haemodialysis
Basic principles of haemodialysis
Fara Dyba
 
Dialysis machine (2)
Dialysis machine (2)Dialysis machine (2)
Dialysis machine (2)
Bew Melesse
 
Principles of-hemodialysis
Principles of-hemodialysisPrinciples of-hemodialysis
Principles of-hemodialysis
FarragBahbah
 
high-flux.pptx
high-flux.pptxhigh-flux.pptx
high-flux.pptx
ayaz9565
 

Similar to Extracorporeal tech (20)

Renal dialysis
Renal dialysisRenal dialysis
Renal dialysis
 
Continuous Renal Replacement Therapy
Continuous Renal Replacement TherapyContinuous Renal Replacement Therapy
Continuous Renal Replacement Therapy
 
renal replacement therapies
renal replacement therapiesrenal replacement therapies
renal replacement therapies
 
Hemodialysis,
Hemodialysis,Hemodialysis,
Hemodialysis,
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
contious Renal replacement therapy
contious Renal replacement therapycontious Renal replacement therapy
contious Renal replacement therapy
 
Continuous renal replacement therapy in icu Crrt 2
 Continuous renal replacement therapy in icu Crrt  2 Continuous renal replacement therapy in icu Crrt  2
Continuous renal replacement therapy in icu Crrt 2
 
Hemodialysis: management of chronic kidney disease
Hemodialysis: management of chronic kidney diseaseHemodialysis: management of chronic kidney disease
Hemodialysis: management of chronic kidney disease
 
Introduction
IntroductionIntroduction
Introduction
 
Continuous renal replacement therapy
Continuous renal replacement therapyContinuous renal replacement therapy
Continuous renal replacement therapy
 
Crrt 2
Crrt  2Crrt  2
Crrt 2
 
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt 2
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt  2CONTINUOUS RENAL REPLACEMENT THERAPY Crrt  2
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt 2
 
Hemodialysis
Hemodialysis Hemodialysis
Hemodialysis
 
Renal dialysis
Renal dialysisRenal dialysis
Renal dialysis
 
Hemodialysis
HemodialysisHemodialysis
Hemodialysis
 
Basic principles of haemodialysis
Basic principles of haemodialysisBasic principles of haemodialysis
Basic principles of haemodialysis
 
Dialysis machine (2)
Dialysis machine (2)Dialysis machine (2)
Dialysis machine (2)
 
Principles of-hemodialysis
Principles of-hemodialysisPrinciples of-hemodialysis
Principles of-hemodialysis
 
high-flux.pptx
high-flux.pptxhigh-flux.pptx
high-flux.pptx
 

Extracorporeal tech

  • 1. Presented by: Arjan Aryal 5th PharmD
  • 2. Patients with ESRD or who have been intoxicated due to overdose of a drug may require supported treatment to remove accumulated drugs.  Methods: Dialysis Hemofiltration Hemoperfusion.  Objective: Rapidly remove undesirable drugs and metabolites without disturbing the fluid and electrolyte balance in the patient.
  • 3.  Artificial Process, acculmulation of drug removed by diffusion into dialysis fluid.  Two Methods:  Peritoneal Dialysis.  Hemodialysis.
  • 4.  Helps to clean the blood and remove excess of water in the body – peritoneal Membrane in the abdomen.  A catheter inserted in peritoneal cavity, dialysis fluid enters into the peritoneal cavity via tube -> filters blood and remove waste products from the body.  Two Types  CAPD(Continous Ambulatory Peritoneal Dialysis)))  APD (Automated Peritoneal Dialysis)
  • 5.  Fluid flows in and out of the body using gravity.  Over time, waste and fluid build up in the blood which slowly float across into peritoneal membrane by diffusion and exchange remove dialysis fluid from the peritoneal cavity and replaces with new fluid.  To be done everyday  1 Exchange takes 30 mins.
  • 6.  Solution is clear.  Check the solution type and % is correct.  Expiration date has not passed.  Volume is correct.  No leaks after gentle squeezing.
  • 7.  Machine does the exchange  Done by Dialysis team or taught to use . FLUID AND DIALYSIS SOLUTION  Important to achieve right balance of water in body.  Determined in 3 ways.  Weight  BP  Swelling  Dialysis Solution  Dianeal (1.5%, 2.5%, 4.25%)  Neutroneal (1.1 %)  Extraneal (7.5%) PRECAUTION Infection
  • 8.  Process that uses artificial kidney to remove waste products through the process called diffusion.  Artificial kidney contains a number of tubes with a semi permeable lining, suspended in a tank filled with dialysing fluid.
  • 9. 1. •One line connected to artery which is connected to one end of dialysis where blood is collected from patient for filtration. 2. •Waste Product from the blood passes into dialysing fluid by diffusion. 3. •Purified Blood is pumped back into the vein which is connected to other end of dialysis device.
  • 10.  Heparin is used to prevent blood clotting during dialysis.  It is much more effective method for rapid removal of drug ( overdose , poisoning) and preferred method in ESRD.  Dialysis may be required from every 2 days to 3 times a week, one dialysis period is of 2-4 hrs depending on patient’s size, weight and renal function. CHARACTERISTICS OF DIALYSING MACHINE  Higher Blood flow rate.  Permeable dialysis membrane.  High Transmembrane pressure. Important notes.
  • 11. •Insoluble or fat soluble drugs are not solubilized.( eg glutethimide – a water insoluble drug.) Water Solubility •Tightly bound protein are not dialysed. (eg propranolol) Protein Binding •Mol Wt less than 500 are dialysed. ( eg Vancomycin is poorly dialysed ) Molecular Weight Drugs with large volume of distribution •Widely distributed drugs are dialysed slowly, drug concentrated in tissues are difficult to remove by dialysis.
  • 12.  In dialysis involving uremic patient receiving drug for therapy, drug is removed depending on the flow rate of the blood to the dialysis machine which is described by the term Dialysance.  Defined by the equation : ClD = Q(Ca –CV) Ca where, Ca = Drug Concentration in arterial blood. CV =Drug Concentration in Venous blood. Q= Rate of Blood flow to kidney. ClD = Dialysance.
  • 13.  Removing the drugs by passing the blood from the patient through an adsorbent material and back to the patient.  Molecules which have greater affinity for the materials will be removed.
  • 14.  Useful in accidental poisoning and drug overdose.  Materials use: ◦ Activated Charcoal (both polar and non polar drugs) ◦ Amberlite resins (non polar organic molecules).
  • 15.  Affinity of the drug for the absorbent.  Surface area of the absorbent.  Absorptive capacity of the absorbent.  Rate of blood flow through the absorbent.  Equilibrium rate of the drug from the peripheral tissue into the blood.
  • 16.  An alternative to hemodialysis and hemoperfusion.  A process by which fluid, electrolytes, small molecular weight substances are removed from the blood using hollow artificial fibre.  Loss of water and electrolytes takes place, that leads to production of ultrafiltrate. As a result equal volume of fluid is replaced.
  • 17.  Synthetic, high flux(permeability), hollow fibre membrane.  Pore size 50000 da  High Surface Area ( 0.6-1.2 m2). Notes • Flow rate of 20-35 ml/kg/hr is usually required. • No benefit shown with higher flow rate, more expensive. • Although higher flow rate may be used if rapid solute clearance is necessary.
  • 18. Hemodialysis involves diffusion across a semipermeable membrane Where as Hemofiltration is a convection process with loss of water Due to ultrafiltration accompanied by convicted loss of salts.
  • 19.  The clearance of the drug depends on sieving coefficient and ultrafiltration rate.  The sieving coefficient reflects the solute removal ability during hemofiltration.  When S=1 solute passes freely through the membrane whereas is S=0 solute is retained in plasma.  S is constant and independent of blood flow , so Cl=S * Ultrafiltration rate  The Concentration of the drug in the ultrafiltrate is also equal to the unbound drug concentration in the plasma , so, amount of drug removed is given as : Amount removed = CP + ∞ * rate of ultrafiltration